TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16129366
Drug: Chemoradiotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoradiotherapy followed by surgery (80 mg/m² cisplatin on day 1, 800 mg/m² fluorouracil on days 1-4, with concurrent radiotherapy of 35 Gy in 15 fractions)
Study: 12538460
Drug: Doxorubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 90 mg/m(2) followed by paclitaxel 250 mg/m(2) (or reverse)
Study: 12538460
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m(2) and paclitaxel 175 mg/m(2)
Study: 10024611
Drug: Prior protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior protein intake of 0.8 g protein. kg‐1. d‐1
Study: 10024611
Drug: Prior protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior protein intake of 1.4 g protein. kg‐1. d‐1
Study: 10024611
Drug: Prior protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior protein intake of 2.0 g protein. kg‐1. d‐1
Study: 10024611
Drug: Amino acid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid‐based formula diet containing 1 g protein. kg‐1. d‐1
Study: 6417996
Drug: Intermittent nasogastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nasogastric feeding (2-h bolus administration)
Study: 21523892
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus plus infusion of tirofiban (n = 24)
Study: 15285862
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose steroid treatment in addition to intravenous antibiotic therapy
Study: 15285862
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic therapy with a single dose placebo
Study: 2344503
Drug: Bendrofluazide 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 10 mg
Study: 3316309
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg
Study: 18407793
Drug: CoQ(10) 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 45 days (Group IV)
Study: 18407793
Drug: CoQ(10) 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 90 days (Group V)
Study: 18407793
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 10 mg twice a day
Study: 16422829
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL saline)
Study: 23585286
Drug: Sulpiride 100
Normalized name: sulpiride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 100 mg dose
Study: 29943744
Drug: Parenteral Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Vitamin D supplementation
Study: 21617262
Drug: Chamomile solution
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile solution (twice-a-day application)
Study: 21617262
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% ointment (once-a-day application)
Study: 16894619
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75 mg/day or 150 mg/day)
Study: 16894619
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Venlafaxine ER or Paroxetine)
Study: 15215096
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg per day
Study: 11800414
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus canreonate (25 mg/day)
Study: 2658637
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment (100, 150, or 200 micrograms/kg at 1 or 2 year intervals)
Study: 29641242
Drug: Acupuncture intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture intervention (weekly or biweekly individualized treatments)
Study: 26141682
Drug: Internet-supported cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-supported cognitive behavioral therapy
Study: 12929019
Drug: Propranolol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administration (group B, n = 20)
Study: 10720043
Drug: Nateglinide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60 mg and 180 mg or 120 mg and 240 mg)
Study: 1547045
Drug: 0.375% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% bupivacaine 10 ml alone
Study: 1547045
Drug: 0.375% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% bupivacaine 10 ml combined with fentanyl 100 micrograms
Study: 4087369
Drug: Transfusion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion at 2 ml/min (Group A)
Study: 4087369
Drug: Transfusion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion at 5 ml/min (Group B)
Study: 4087369
Drug: Transfusion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion at 10 ml/min (Group C)
Study: 4087369
Drug: Transfusion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion at 5 ml/min with 40 mg furosemide (Group D)
Study: 29846530
Drug: Andecaliximab 150
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab 150 mg every 2 weeks (Q2W)
Study: 29846530
Drug: Andecaliximab 150
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab 150 mg weekly (QW)
Study: 29846530
Drug: Andecaliximab 300
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab 300 mg weekly (QW)
Study: 27515515
Drug: Immediate-release melatonin
Normalized name: melatonin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release melatonin (3 mg) administered daily at 21:00 ± 1 h from day 1 to day 28 of admission
Study: 21203698
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) (830 nm, 15 mW, 12 J/cm²) daily from the 1st day until the end of RT for 5 consecutive days
Study: 21203698
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (AH) 310 mg/5 mL, 4 times/day throughout the duration of RT
Study: 14667696
Drug: Living kind
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living kind concepts at different hierarchical levels (e.g. tree, oak)
Study: 11697755
Drug: Intravenous lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lorazepam (2 mg)
Study: 11697755
Drug: Intramuscular lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lorazepam (2 mg)
Study: 11697755
Drug: All routes
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All routes (Intranasal, Intravenous, Intramuscular)
Study: 8180641
Drug: DTaP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP vaccine (0.5 mL, intramuscularly)
Study: 8180641
Drug: DTwP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP vaccine (0.5 mL, intramuscularly)
Study: 8180641
Drug: Both DTaP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both DTaP and DTwP vaccines
Study: 3282463
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate 200 mg/m2 body surface area for 5 days by continuous intravenous infusion
Study: 3282463
Drug: Calcitonin 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin 8 IU/kg body weight every 6 hours for 5 days by intramuscular injection
Study: 28929258
Drug: Serotonin (5-HT)
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin (5-HT) administered via intraventricular injection
Study: 28929258
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DA) administered via intraventricular injection
Study: 26659927
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of terlipressin (TERLI-INF group) at an initial dose of 2 mg/day
Study: 26659927
Drug: Intravenous boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous boluses of terlipressin (TERLI-BOL group) at an initial dose of 0.5 mg every 4 hours
Study: 26659927
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of terlipressin (TERLI-INF group)
Study: 26659927
Drug: Intravenous boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous boluses of terlipressin (TERLI-BOL group)
Study: 20350430
Drug: Gradual drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual drug withdrawal after a 12-week treatment course
Study: 20350430
Drug: Immediate drug
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate drug withdrawal
Study: 18444136
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin E and selenium
Study: 14650707
Drug: 20-mg enalapril
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg enalapril tablets (test product)
Study: 14650707
Drug: 20-mg enalapril
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg enalapril tablets (reference product)
Study: 9170118
Drug: Cyclandelate (Natil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (Natil, 1,600 mg/day)
Study: 1313163
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + glucomannan (approx. 4 g/die in 3 doses)
Study: 1313163
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet therapy alone
Study: 31204473
Drug: 3-Hydroxybenzo[a]pyrene glucuronide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-Hydroxybenzo[a]pyrene glucuronide (BaP-3-G)
Study: 17585375
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.5% timolol maleate
Study: 7887637
Drug: Cisplatin-based combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based combination chemotherapy followed by chest irradiation
Study: 7887637
Drug: Radiotherapy in
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy in combination with chemotherapy
Study: 3040923
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy
Study: 7887637
Drug: Weekly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly chemotherapy (increased dose intensity)
Study: 7887637
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs (CPT-11, taxol, axotere, vinorelbine, gemcitabine)
Study: 1919301
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron absorption
Study: 30819228
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (reminder via cellphone text message/call or bottle-based flash/alarm, plus monthly counseling)
Study: 30819228
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (standard counseling at routine monthly clinic visits)
Study: 29291768
Drug: Mothering from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothering from the Inside Out (MIO) treatment
Study: 27568506
Drug: Internet-based smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based smoking cessation intervention combined with tele-health medication clinic for nicotine replacement therapy (NRT)
Study: 25306746
Drug: Amaltea goat's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amaltea goat's milk 200 ml/day during basic therapy
Study: 25306746
Drug: Traditional basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional basic dietary therapy
Study: 20153029
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler)
Study: 15459602
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2000 mg/dose, n = 95
Study: 10937408
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B education/promotion curriculum package; administered over 4 class periods before vaccination.
Study: 1569973
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus plasmapheresis
Study: 1569973
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (prednisone and cyclophosphamide)
Study: 3865246
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg DEX (dexamethasone) administered at 2300 h
Study: 3865246
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg DEX (dexamethasone) administered at 2300 h
Study: 30484332
Drug: US‐TAP block
Approvals — FDA: no, EMA: no, PMDA: no
Description: US‐TAP block with 20 mL of 0.35% ropivacaine
Study: 27511476
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (N) monotherapy
Study: 25527666
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-infected infants
Study: 25527666
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-exposed infants
Study: 25527666
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentrations <10 ng/mL for HIV-infected infants
Study: 25527666
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentrations <10 ng/mL for HIV-exposed infants
Study: 21655990
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg o.d. for 1 week, then 1 g b.d. for 1 week)
Study: 21655990
Drug: Internal control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal control (no treatment for 1 week)
Study: 21655990
Drug: Metformin (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (same dose regimen as above)
Study: 14601275
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg propofol (group A)
Study: 14601275
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg propofol (group B)
Study: 14601275
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg propofol (test-dose)
Study: 14601275
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between test-dose and induction-dose
Study: 10854683
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isradipine plus 5 mg enalapril
Study: 10854683
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isradipine
Study: 10854683
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of isradipine plus enalapril
Study: 1425871
Drug: Acipimox (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (doses: 31.2, 62.5, 125.0, 250.0 mg)
Study: 6378522
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg t.i.d.) and dipyridamole (75 mg t.i.d.)
Study: 26853497
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour treatment program (Cool Kids)
Study: 24525115
Drug: MOSF (15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOSF (15% Fish oil, 30% Medium‐chain triglycerides, 25% Olive oil, 30% Soybean oil) at 3.5 g kg(‐1) d(‐1)
Study: 24525115
Drug: MOSF (15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOSF (15% Fish oil) at 2.5 g kg(‐1) d(‐1)
Study: 8388918
Drug: Vincristine (VCR)
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine (VCR) and Dactinomycin (AMD) for 38 weeks (L)
Study: 3551160
Drug: Multiple chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple chemotherapeutic agents
Study: 3551160
Drug: Single chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single chemotherapeutic agents
Study: 21853386
Drug: Clodronate 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 300 mg i.v. for 7 days, followed by clodronate i.m. 100 mg for 14 days every 3 months (Group A)
Study: 21853386
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg daily for 30 days, followed by 200 mg daily for the next 11 months (Group B)
Study: 15649655
Drug: 3 cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cups (450 mL) of filtered coffee for 3 weeks
Study: 15649655
Drug: 6 cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cups (900 mL) of filtered coffee for 3 weeks
Study: 15649655
Drug: 1 cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cup (150 mL) of coffee (single dose)
Study: 15649655
Drug: 2 cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cups (300 mL) of coffee (single dose)
Study: 12469330
Drug: Colestipol hydrochloride
Normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol hydrochloride (colestipol) administered with diltiazem SR
Study: 17803064
Drug: HEP1 (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP1 (human ezrin peptide 324‐337; TEKKRRETVEREKE) monotherapy
Study: 16024305
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for 4-8 weeks
Study: 8880815
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal ketamine (5‐6 mg.kg‐1)
Study: 8880815
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (5‐6 mg.kg‐1)
Study: 8880815
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine (5‐6 mg.kg‐1)
Study: 3930990
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose naloxone (2 mg/kg)
Study: 3930990
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naloxone (0.4 mg, approx. 5 micrograms/kg)
Study: 3663882
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg controlled-release (CR) albuterol tablet (q12h)
Study: 3663882
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg conventional albuterol tablet (q6h)
Study: 15193678
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg twice daily
Study: 31665385
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with an egg and 150 mL of cow milk for 90 days, and 1 sachet of multiple micronutrient powder for 60 days.
Study: 20463260
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (tailored exercise prescription + transtheoretical behavior change counseling)
Study: 20463260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (exercise prescription alone)
Study: 12701337
Drug: APAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP treatment (n = 50)
Study: 12701337
Drug: Conventional CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CPAP treatment (n = 50)
Study: 9557050
Drug: Mucosolvan (mucolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosolvan (mucolytic preparation)
Study: 1304021
Drug: Spiramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiramycin (1 gram twice daily)
Study: 1304021
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg thrice or four times daily)
Study: 27010957
Drug: Omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 300 mg every 4 weeks up to week 24
Study: 24296715
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor antagonist (exendin-9)
Study: 26076755
Drug: Contextual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contextual Cognitive Behavioural Therapy (CCBT)
Study: 23764140
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) physiotherapy